(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 December 2007 (13.12.2007)

PCT

(10) International Publication Number
WO 2007/143422 A3

(51) International Patent Classification:
C07D 213/81 (2006.01) *A61P 25/00* (2006.01)
A61K 31/44 (2006.01)

(21) International Application Number:
PCT/US2007/069723

(22) International Filing Date: 25 May 2007 (25.05.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/803,407 30 May 2006 (30.05.2006) US
60/823,108 22 August 2006 (22.08.2006) US

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KEITH, John M.** [US/US]; 16724 Alondra Drive, San Diego, California 92128 (US). **LETAVIC, Michael A.** [US/US]; 4379 Mistral Place, San Diego, California 92130 (US). **LY, Kiev S.** [US/US]; 7924 Avenida Navidad, #124, San Diego, California 92122 (US). **MANI, Neelakandha S.** [IN/US]; 13109 Russet Leaf Lane, San Diego, California 92129 (US). **MILLS, John E.** [US/US]; 643 Sourwood Drive, Hatfield, Pennsylvania 19440 (US). **PANDIT, Chennagiri R.** [US/US]; 12894 Amaranth Street, San Diego, California 92129 (US). **VILLANI, Frank J.** [US/US]; 2 Pinewood Lane, Perkasie, Pennsylvania 18944 (US). **ZHONG, Hua** [US/US]; 1625 Holly Hill Lane, Maple Glen, Pennsylvania 19002 (US).

(74) Agents: **JOHNSON, Phillip S.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
7 February 2008

(54) Title: SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR



(I)

(57) Abstract: Pyridylamide compounds of Formula: (I); wherein R^1 is -C_{1-4}alkyl or saturated monocyclic cycloalkyl; m is 1 or 2; X is N or CH; Y is N or CR^3; R^a is -H, -Z-Ar, -$CH_2NR^bR^c$, -CN, -CO_2C_{1-4}alkyl, -CO_2H, or -$CONR^bR^c$; where R^b and R^c are each independently -H or -C_{1-4}alkyl; and R^2 is -H or -Z-Ar; with the proviso that one of X and Y is N and one of R^a and R^2 is -Z-Ar; where Z is O or S; and Ar is a phenyl or monocyclic heteroaryl group unsubstituted or substituted with one, two, or three R^3 substituents; where each R^3 substituent is independently selected from the group consisting of: halo, -C_{1-4}alkyl, -OH_1 -OC_{1-4}alkyl, -SC_{1-4}alkyl, -CN, -$CONR^dR^e$, and -NO_2; where R^d and R^e are each independently -H or -C_{1-4}alkyl; are histamine H_3 receptor modulators useful in the treatment of histamine H_3 receptor-mediated1 diseases.

WO 2007/143422 A3